reldesemtiv
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease
Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease
Cytokinetics shares positive phase 3 results for aficamten in heart disease
Up to one in 500 people in the UK and US are living with hypertrophic cardiomyopathy
Eli Lilly and Alchemab Therapeutics enter ALS agreement worth up to $415m
The deal follows the companies’ earlier partnership to advance candidates for the neurodegenerative disease
Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies
The neurodegenerative disease affects approximately 30,000 people in the US
Biogen’s Qalsody granted EC approval to treat rare form of ALS in adults
Mutations in the SOD1 gene are responsible for an estimated 2% of all ALS cases
Biogen’s Qalsody recommended by CHMP to treat rare form of ALS
Mutations in the SOD1 gene are responsible for approximately 2% of all ALS cases
Innovate UK awards Sano Genetics £330,000 grant for ALS study
The project will chart the psychological impacts of having a genetic predisposition to ALS
Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS
Mutations in the SOD1 gene are responsible for approximately 2% of all cases
Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure
The neurodegenerative disease affects approximately 27,000 people in the US
Biogen and Alcyone Therapeutics partner in deal worth over $50m
The companies hope to improve treatments for spinal muscular atrophy and amyotrophic lateral sclerosis
Verge Genomics begins human trials with AI-sourced ALS drug
VRG50635 was discovered by the company’s all-in-human, AI-powered platform